GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT03724981

CompletedPhase 4Results posted

A Study Comparing the Dulaglutide Pen and the Semaglutide Pen

Crossover Study Comparing the Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen

Lead sponsor

Eli Lilly and Company

Assets

Dulaglutide / Semaglutide

Listed sites

Recruiting sites

—

Enrollment

312

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoints

•PGI, change•Participant Preference Between 2 Injection Devices

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03724981

Org study ID17155

Secondary IDH9X-MC-B021Eli Lilly and Company

Timeline

Milestones

Study start2018-10-18actual

Study first posted2018-10-30actual

Primary completion2019-04-12actual

Study completion2019-04-12actual

Last update posted2020-04-24actual

Results first posted2020-04-24actual

Assets

Investigational agents

Dulaglutide Semaglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Diagnosed with type 2 diabetes

•Self-injection naïve to all injectable treatment (for example, diabetes therapies and other medical conditions)

•Injection naïve to performing all injectable treatment (for example, diabetes therapies and other medical conditions) to others

Exclusion criteria

•Currently diagnosed with gestational diabetes and/or type 1 diabetes

•Cognitive or physical difficulties that could interfere with ability to understand the training, perform the injection tasks, or complete the study questionnaires as judged by the investigator

•Is a health care practitioner who is trained in giving injections

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Patient-reported / QoL

4 endpoints

Primary/registry result

Participant Preference Between 2 Injection Devices Based on Global Preference Item

Time frame:Day 1

PGI, change

threshold achievement, improvement

Posted result

Group	Value (number), percentage of participants	95% CI
Dulaglutide to SemaglutideDulaglutide Device Preference	87.7	—
No Device Preference	2.6	—
Semaglutide Device Preference	9.7	—
Semaglutide to DulaglutideDulaglutide Device Preference	80.6	—
No Device Preference	4.5	—
Semaglutide Device Preference	14.8	—

p<0.0001Prescott test

Primary/protocol endpoint

Participant Preference Between 2 Injection Devices Based on Global Preference Item

Time frame:Day 1

categorical status, descriptive

Secondary/registry result

Participant Preference Between 2 Injection Devices Based on Ease of Use

Time frame:Day 1

categorical status, descriptive

Posted result

Group	Value (number), percentage of participants	95% CI
Dulaglutide to SemaglutideDulaglutide Device Preference	87.1	—
No Device Preference	5.2	—
Semaglutide Device Preference	7.7	—
Semaglutide to DulaglutideDulaglutide Device Preference	86.5	—
No Device Preference	7.7	—
Semaglutide Device Preference	5.8	—

p<0.0001Prescott test

Secondary/protocol endpoint/low confidence

Participant Preference Between 2 Injection Devices Based on Ease of Use

Time frame:Day 1

PGI, change

categorical status, descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER).
Diabetes, obesity & metabolism2020 Mar (month)PMID31646727doi:10.1111/dom.13902via CT.gov background

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.